Please login to the form below
niraparib
This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube
Latest news
-
EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer
That includes GlaxoSmithKline’s (GSK) Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).
-
FDA accepts review to broaden GSK’s Zejula label
GSK is seeking approval for Zejula (niraparib) as a first-line maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status.
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
GSK took full ownership of the therapy in 2018. GSK’s push into cancer has also included its $5.1bn acquisition of Tesaro, which brought in PARP inhibitor Zejula (niraparib).
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck &Co’s market-leading Lynparza (olaparib), GlaxoSmithKline/Janssen’s Zejula (niraparib) and Pfizer’s new entrant Talzenna (talazoparib) to
-
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer
If the FDA backs the new indication it will help AZ and Merck to maintain their lead over newer rivals in the PARP inhibitor class, including GlaxoSmithKline’s Zejula (niraparib), Clovis
More from news
Approximately 4 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Deal Watch April 2016
Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
